Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-07-30

Clinical Trial Update: Intravitreal Faricimab in Patients With Refractory Macular Edema [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating intravitreal faricimab for refractory macular edema in age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Faricimab (Vabysmo) (faricimab)

Snippet

Sponsor: University of Baghdad | Conditions: Age-Related Macular Degeneration | Phase 2 | Status: COMPLETED